Jefferies Financial Group Comments on DexCom, Inc.’s Q3 2019 Earnings (DXCM)

DexCom, Inc. (NASDAQ:DXCM) – Analysts at Jefferies Financial Group issued their Q3 2019 earnings per share (EPS) estimates for shares of DexCom in a research note issued to investors on Tuesday, November 6th. Jefferies Financial Group analyst R. Denhoy anticipates that the medical device company will post earnings of $0.00 per share for the quarter. Jefferies Financial Group has a “Buy” rating and a $148.00 price target on the stock. Jefferies Financial Group also issued estimates for DexCom’s Q4 2019 earnings at $0.21 EPS.

DexCom (NASDAQ:DXCM) last posted its earnings results on Tuesday, November 6th. The medical device company reported $0.17 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.12) by $0.29. DexCom had a net margin of 4.72% and a negative return on equity of 3.08%. The business had revenue of $266.70 million for the quarter, compared to analysts’ expectations of $242.72 million. DexCom’s quarterly revenue was up 44.5% compared to the same quarter last year.

Several other analysts have also recently issued reports on DXCM. BidaskClub cut shares of DexCom from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 31st. Piper Jaffray Companies increased their target price on shares of DexCom to $150.00 and gave the stock an “overweight” rating in a research note on Thursday, August 2nd. Oppenheimer set a $125.00 target price on shares of DexCom and gave the stock a “buy” rating in a research note on Thursday, August 2nd. JPMorgan Chase & Co. increased their target price on shares of DexCom to $140.00 and gave the stock an “overweight” rating in a research note on Thursday, August 2nd. Finally, BMO Capital Markets increased their target price on shares of DexCom from $112.00 to $125.00 and gave the stock an “outperform” rating in a research note on Thursday, August 2nd. Eight investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $132.50.

NASDAQ DXCM opened at $148.41 on Thursday. DexCom has a 1 year low of $49.17 and a 1 year high of $152.14. The company has a debt-to-equity ratio of 0.69, a quick ratio of 4.62 and a current ratio of 4.89. The company has a market capitalization of $11.74 billion, a price-to-earnings ratio of -255.88 and a beta of 0.60.

Several institutional investors have recently bought and sold shares of the company. Crossmark Global Holdings Inc. purchased a new stake in shares of DexCom during the 3rd quarter valued at $264,000. Piedmont Investment Advisors Inc. purchased a new stake in shares of DexCom during the 3rd quarter valued at $904,000. Swiss National Bank raised its position in shares of DexCom by 1.0% during the 3rd quarter. Swiss National Bank now owns 153,600 shares of the medical device company’s stock valued at $21,971,000 after buying an additional 1,500 shares in the last quarter. Weil Company Inc. purchased a new stake in shares of DexCom during the 3rd quarter valued at $271,000. Finally, IBM Retirement Fund purchased a new stake in shares of DexCom during the 3rd quarter valued at $203,000.

In other news, insider Jacob Steven Leach sold 47,600 shares of the firm’s stock in a transaction on Friday, September 28th. The shares were sold at an average price of $143.95, for a total transaction of $6,852,020.00. Following the sale, the insider now owns 109,284 shares in the company, valued at approximately $15,731,431.80. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Patrick Michael Murphy sold 400 shares of the firm’s stock in a transaction on Wednesday, October 10th. The shares were sold at an average price of $122.20, for a total transaction of $48,880.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 157,892 shares of company stock worth $21,864,030. Corporate insiders own 1.80% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Featured Story: Balance Sheet

Earnings History and Estimates for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply